JayBWishMD

PubMed

• Dialysis Technician Burnout: An Opportunity for Empowerment.
  Hanna Webb, Jay B Wish> ;American Journal of Kidney Diseases. 2023 Apr 28
• 1 citations
  Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
  Jay B Wish, Pablo Pergola> ;Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 2022 Dec 1
• Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey.
  Steven N Michalopoulos, Marjolaine Gauthier-Loiselle, Myrlene Sanon Aigbogun, Elizabeth Serra, Rebecca Bungay, Diana Clynes, Martin Cloutier, Erin Kahle, Annie Guérin,...> ;Kidney Medicine. 2022 Apr 1
• 5 citations
  Past, Present, and Future of Phosphate Management.
  Simit M Doshi, Jay B Wish> ;Kidney International Reports. 2022 Apr 1
• Kidney disease and congenital heart disease: Partnership for life.
  Skye El Sayegh, Georges Ephrem, Jay B Wish, Sharon Moe, Kenneth Lim> ;Frontiers in Physiology. 2022 Jan 1
• Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
  Jay B Wish> ;American Journal of Nephrology. 2022 Jan 1
• 1 citations
  Untangling the Association between Anemia Treatment and Stroke Risk in CKD.
  Jay B Wish> ;Kidney360. 2021 Nov 25
• 2 citations
  Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
  Jonathan W. Bazeley, Jay B. Wish> ;American Journal of Kidney Diseases. 2021 Nov 7
• 2 citations
  Iron Deficiency in CKD Without Concomitant Anemia
  Jay B. Wish, Stefan D. Anker, Javed Butler, Aleix Cases, Austin G. Stack, Iain C. Macdougall> ;Kidney International Reports. 2021 Aug 10
• 6 citations
  Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation
  Jay B. Wish, Kai-Uwe Eckardt, Csaba P. Kovesdy, Steven Fishbane, Bruce Spinowitz, Jeffrey S. Berns> ;American Journal of Kidney Diseases. 2021 Jul 28
• Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle.
  Jay B. Wish> ;Kidney International Reports. 2021 Jun 23
• 1 citations
  Treatment of Anemia in Kidney Disease: Beyond Erythropoietin.
  Jay B. Wish> ;Kidney International Reports. 2021 Jun 9
• 6 citations
  Strategies to Reduce Rehospitalization in Patients with CKD and Kidney Failure.
  Simit Doshi, Jay B. Wish> ;Clinical Journal of the American Society of Nephrology. 2021 Feb 8
• 1 citations
  Balancing Nephrology Referrals With Nephrologist Capacity to Decrease Emergency Dialysis Starts.
  M. Yahya Jan, Jay B. Wish> ;Kidney International Reports. 2021 Jan 1
• 2 citations
  Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
  Jay B. Wish> ;Kidney Medicine. 2020 Aug 25
• 3 citations
  Is It Time for Precision Dialysis
  Nupur Gupta, Jay B. Wish> ;Clinical Journal of the American Society of Nephrology. 2021 Feb 8
• 19 citations
  Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
  Tomas Ganz, George R. Aronoff, Carlo A. J. M. Gaillard, Lawrence T. Goodnough, Iain C. Macdougall, Gert Mayer, Graça Porto, Wolfgang C. Winkelmayer, Jay B. Wish> ;Kidney Medicine. 2020 May 1
• 1 citations
  Are Dialysis Facility Quality Incentive Program Scores Associated With Patient Survival
  Nupur Gupta, Jay B. Wish> ;American Journal of Kidney Diseases. 2020 Feb 1
• 1 citations
  Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?
  Jay B. Wish> ;Kidney International Reports. 2019 Jul 11
• 1 citations
  Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?
  Jay B. Wish> ;Advances in Chronic Kidney Disease. 2019 Jul 1
• 1 citations
  Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies.
  Jay B. Wish, Marcelo G. Rocha, Nancy E. Martin, Christian Russel D. Reyes, Steven Fishbane, Mark T. Smith, George M. Nassar> ;Kidney Medicine. 2019 Sep 1
• 3 citations
  The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease.
  Jonathan W. Bazeley, Jay B. Wish> ;Advances in Chronic Kidney Disease. 2019 Jul 1
• 9 citations
  Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective.
  Matti Aapro, Pere Gascón, Kashyap Patel, George M. Rodgers, Selwyn Fung, Luiz H. Arantes, Jay B. Wish> ;Frontiers in Pharmacology. 2019 Jan 9
• 5 citations
  Leading the Dialysis Unit: Role of the Medical Director
  Sharmeela Saha, Jay B. Wish> ;Advances in Chronic Kidney Disease. 2018 Nov 1
• 4 citations
  Difficult Patient Behavior in Dialysis Facilities.
  Danielle Janosevic, Aileen X. Wang, Jay B. Wish> ;Blood Purification. 2019 Jan 1
• Join now to see all

Journal Articles

• Biosimilars—Emerging Role in Nephrology  
  Jay Wish, MD, Journal of the American Society of Nephrology
• Epidemic end-stage renal disease and nephrology manpower trends: crisis or opportunity?  
  McClellan WM, Cangialose C, Wish JB, Semin Dial 8:275-282
• Safety of intravenous iron dextran in hemodialysis patients.  
  Fishbane S. Ungureanu V, Maesaka JK, Kaupke CJ, Lim V, Wish J, Am J Kidney Dis 28:529-534
• Improving the care of ESRD patients: A success story.  
  McClellan WM, Frankenfield DL, Frederick PR, Helgerson SD, Wish JB, Sugarman JR, Health Care Financ Rev 24:89-100
• Hydralazine-induced ANCA-positive pauci-immune glomuerulonephritis: a case report and literature review.  
  Dobre M, Wish J, Negrea L, Ren Fail 31:745-748
• Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure.  
  Lilly MP, Lynch JR, Wish JB, et al, Am J Kidney Dis 59:541-9
• Preventing radiocontrast-induced acute renal failure.  
  Wish JB, Moritz CE, J Crit Illn 5(1):16-31
• Impotence.  
  Seftel AD, Sweeney P, Wish JB, Semin Dial 7:20-22
• Quality control in the ESRD program.  
  Norwalk, CT, Adv Renal Replac Ther 2(2):83-188
• A consensus on current issues and controversies in iron management in patients with chronic renal failure.  
  Adamson J, Cavill I, Fishbane S, Peterson J, Wish JB, Semin Dial 12:182-194
• Economic issues and future directions in iron management.  
  Wish JB, Semin Dial 12:267-270
• Reports from the ESRD Networks.  
  Wish JB, Adv Renal Replac Ther 7 (4, Suppl.1):S1-S104
• Continuous quality improvement in dialysis units.  
  Pastan S, Wish JB, Adv Renal Replac Ther 8:87-88
• Quality oversight of dialysis in the United States.  
  Wish JB, Korean J Nephrol 21 (Suppl 2):S188-S189
• Application of continuous quality improvement: benefits and barriers.  
  Wish JB, Korean J Nephrol 21(Suppl 2):S194-S196
• The economic realities of erythropoiesis-stimulating agent therapy in kidney disease.  
  Wish JB, Kidney Int 70 (Suppl 104):S21-S25
• ESRD Networks: Past, Present, and Challenges for the Future.  
  Wish JB, Meyer KB, Clin J Am Soc Nephrol
• The Controversies in Surveillance: Can It Prolong AV Access Patency? Yes: If Treatment of Stenosis Worked Better.  
  Wish JB, J Vasc Access 12(suppl 4) S22-S23
• Join now to see all

Books/Book Chapters

• Management of Medical Problems in Surgical Patients. 
  Chapter: Renal disease and hypertension 
  Wish JB, Cohen JJEditors: Molitch ME.FA Davis Co, Philadelphia
• Therapy of Renal Diseases and Related Disorders. 
  Chapter: Disorders of potassium metabolism 
  Kassirer JP, Wish JBEditors: Suki WN, Massry SG.Martinus Nijhoff Publishers, The Hague
• Cecil Essentials of Clinical Medicine. 
  Chapter: Metabolic diseases 
  Hricik DH, Wish JBEditors: Andreoli TE, et al.WB Saunders Co, Philadelphia
• Oxford Textbook of Rheumatology. 
  Chapter: Renal involvement rheumatic disease 
  Wish JB, Kammer GMEditors: Maddison PJ, et al.Oxford University Press, Oxford
• The High Risk Patient: Management of the Critically Ill. 
  Chapter: Acid-base and electrolyte disorders 
  Wish JB, Cacho CMEditors: Sivak ED, et al.Lea and Fegiber, Philadelphia
• Clinical Dialysis. 
  Chapter: Assuring quality of care in dialysis patients 
  Wish JBEditors: Nissenson AR, Fine RN, Gentile DE.Andover Publishing, Norwalk, CTEdition 3,
• Oxford Textbook of Rheumatology. 
  Chapter: Renal involvement in rheumatic disease 
  Cacho CM, Kammer GM, Wish JBEditors: Maddison PJ, et al.Oxford University Press, OxfordEdition 2,
• Principles and Practice of Dialysis. 
  Chapter: Hemodialysis adequacy 
  Lacson E, Wish JBEditors: Henrich WL.Williams and Wilkins, BaltimoreEdition 2,
• Dialysis and Transplantation: A Companion to Brenner and Rector’s The Kidney. 
  Chapter: Algorithms and care paths for quality improvement 
  Wish JB, Blondin JEditors: Owen WF, Periera BJG, Sayegh.W.B. Saunders, Orlando
• Nephrology Secrets. 
  Chapter: Anemia associated with renal failure, technical aspects of hemodialysis, metabolic acidosis, metabolic alkalosis 
  Wish JBEditors: Hricik DE, Sedor JR, Ganz MB.Hanley and Belfus, Philadelphia
• Dialysis Therapy. 
  Chapter: Quality improvement 
  Wish JBEditors: Nissenson AR, Fine RN.Hanley and Belfus, Philadelphia
• Dialysis Therapy. 
  Chapter: Quality improvement 
  Wish JBEditors: Nissenson AR, Fine RN.Hanley & Belfus, Inc, PhiladelphiaEdition 3,
• Nephrology Secrets. 
  Chapter: Anemia associated with renal failure, technical aspects of hemodialysis, management of patients with progressive renal failure, hemodialysis: assessing adequacy 
  Wish JBEditors: Hricik DE, Miller RT, Sedor JR.Hanley and Belfus, PhiladelphiaEdition 2,
• Principles and Practice of Dialysis, third edition. 
  Chapter: Hemodialysis adequacy and the timing of dialysis initiation 
  O’Connor AS, Wish JBEditors: Henrich WL.Lippincott Williams & Wilkins, Philadelphia
• Clinical Dialysis. 
  Chapter: Quality, safety and accountability in dialysis 
  Wish JBEditors: Nissenson AR, Fine RN.McGraw Hill, New YorkEdition 4,
• Primer on Kidney Diseases. 
  Chapter: Hematologic manifestations of chronic kidney disease 
  Wish JBEditors: Greenberg A.Saunders, Philadelphia
• Principles and Practice of Dialysis. 
  Chapter: Hemodialysis adequacy and the timing of dialysis initiation 
  O’Connor AS, Wish JBEditors: Henrich WL.Lippincott Williams & Wilkins, Philadelphia
• Join now to see all

Abstracts/Posters

• Comparison of platelet activation by polyacrylonitrile and cuprophan dialysis membranes.
  Marchant KK, Anderson JM, Smith MC, Wish JB, ASN Annual Meeting
• Effect of polyacrylonitrile and cuprophan dialysis membranes on white blood cell and complement component activation.
  Ludgin JR, Naff GB, Spagnuolo P, Wish JB, ASN Annual Meeting
• Nature and severity of vascular access complications in chronic hemodialysis patients.
  Wish JB, Sharp WV, ASN Annual Meeting
• Characterization of the circulating insulin resistance factor associated with uremia.
  McCaleb ML, Wish JB, Izzo MS, Freeman RB, Lockwood DH, ASCI Annual Meeting
• Insulin resistance in uremia is due to a post insulin receptor kinase defect(s).
  Caro JF, Sinha MK, McCaleb ML, Wish JB, Lockwood DH, AFCR Annual Meeting
• Medical appropriateness of initiating chronic dialysis in the U.S.: results of the revised medical evidence report pilot study.
  Wish JB, Webb RL, Levin AS, Port FK, Held PJ, J Am Soc Nephro. 5:345
• Efficacy of ESRD medical evidence screening procedures.
  Segeida GE, Sarsitis I, Wish JB, Coomer R, Eggers P, Stark S, Port FK, Held PJ, J Am Soc Nephrol 8:224A
• management and Hct control in hemodialysis patients. A report from the 1997 HCFA Core Indicators Project.
  Wish JB, Frankenfield DL, Frederick PR, Owen WF, Johnson CA, Rocco MV, J Am Soc Nephrol 9:230A
• Continued improvement in anemia management in hemodialysis patients: Report from the 1998 HCFA Core Indicators Project.
  Johnson CA, Frankenfield DL, Rocco MV, Wish JB, J Am Soc Nephrol.10:169A
• Physician activity reporting: Is it worthwhile?
  Paganini EP, Stark S, Wish J, Aronoff G, Mutterperl R, J Am Soc Nephrol 10:252A
• Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 ESRD Core Indicators Project.
  McClellan WM, Frankenfield DL, Johnson CA, Rocco MV, Wish JB, Owen WF, J Am Soc Nephrol 11:287A
• Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: Results from the 1998 ESRD Core Indicators Project.
  McClellan WM, Frankenfield DL, Johnson CA, Owen WF, Rocco MV, Wish JB, J Am Soc Nephrol 11:287A
• Regional variability in anemia management and hemoglobin in the U.S.
  Reddan D, Frankenfield D, Klassen P, Coladonado J, Szczech L, Johnson C, Besarab A, Rocco M, McClellan W, Wish J, Owen W, J Am Soc Nephrol 12:344A
• Correlation between vascular access type, hemoglobin levels, and EPO dose in prevalent hemodialysis patients.
  Wish JB, Brier ME, Kao PF, Aronoff GR, J Am Soc Nephrol 12:419A
• The effectiveness of clinical performance measures in hemodialysis patients.
  O’Connor AS, Wish JB, Sehgal AR, J Am Soc Nephrol 14:254-255A
• Intravenous iron use among adult hemodialysis patients: Results from the 2002 ESRD Clinical Performance Measures Project.
  Johnson CA, Frankenfield DL, Wish JB, J Am Soc Nephrol 11:458A
• Correlation between vascular access type hemoglobin level, and Epo dose in prevalent hemodialysis patients: a cohort evaluation of the Renal Network Data System (TRN...
  Teo BW, Kalahasti P, Chand DH, et al, Wish J, J Am Soc Nephrol 16:464A
• Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease appears to be limited to patients with low dose requirements.
  Wish J, Law AW, Schulman KL, Am J Kidney Dis 47:A62
• Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease appears to be limited to patients with low dose requirements.
  Wish J, Law AW, Schulman KL, Am J Kidney Dis 47:A61
• Prevalence and treatment of absolute iron deficiency in U.S. hemodialysis patients: findings from the 2005 ESRD Clinical Performance Measures Project.
  Wish JB, Johnson CA, Frankenfield DL, Besarab A, J Am Soc Nephrol 17:320A,
• A retrospective claims analysis of anemia treatment patterns in patients with chronic kidney disease with and without diabetes.
  Wish J, Schulman K, Law A, del Aguila M, J Am Soc Nephrol 17:155A
• Medication burden in patients with chronic kidney disease with and without erythropoiesis-stimulating agents.
  Wish J, Schulman K, Law A, del Aguila M, J Am Soc Nephrol 17:617A
• Cost burden of anemia in predialysis cohort of patients with chronic kidney disease.
  Wish J, Schulman K, Law A, J Am Soc Nephrol 17:617A
• The effects of consistent erythropoiesis-stimulating agent use prior to onset of dialysis on cardiovascular outcomes: a retrospective claims database analysis.
  Wish J, Schulman K, del Aguila M, Nassar G, Provenzano R, Hemodial Int 11:133
• Why are catheters still the predominant initial HD access in the US and what effectively reduces their use?
  Wish JB, J Vasc Access 13(suppl 5) S23-S24
• Join now to see all